Cytori Therapeutics Inc. (CYTX) unveiled a pact to commercialize the company's cell therapies for the cardiovascular, renal and diabetes markets in Australia and several Asian nations. Shares of Cytori soared 46% to $3.05 after hours, after the company said partner Lorem Vascular will pay up to $500 million in fees for a 30-year exclusive license to Cytori. http://bigcharts.marketwatch.com/quickchart/quickchart.asp?s...
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by